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TO THE EDITOR
Proteus syndrome (PS) is characterized
by progressive, mosaic, segmental
overgrowth and occurs sporadically
(Biesecker, 2001; 2006). The mosaic
nature and sporadic occurrence with
the lack of familial transmission led
to the hypothesis that PS is caused
by a post-zygotic somatic mutation,
which was confirmed with the discovery
of a mosaic activating c.49G4A,
p.Glu17Lys AKT1 mutation (Lindhurst
et al., 2011). To date, all patients who
meet the clinical diagnostic criteria for
PS and have been tested have this
mutation (MJ Lindhurst and LG
Biesecker, unpublished results).
Although any organ or tissue can be
affected, skeletal overgrowth and der-
matologic lesions are the most common
manifestations of PS (Turner et al., 2004;
Beachkofsky et al., 2010). Cerebriform
connective tissue nevi (CCTN) are a
highly specific and common lesion in
patients with PS (Biesecker, 2001;
Nguyen et al., 2004). These lesions
are very firm and contain deep sulci
that resemble the brain, thus giving
the lesion its name. Histology sections
of CCTN show massively expanded
dermis filled with thick collagen
bundles (Figure 1d–f) (McCuaig et al.,
2012). Epidermal nevi (EN) can be
non-syndromic or occur as part of
several syndromes including PS
(Happle, 2010). The keratinocytic EN
found in PS have a rough surface, are
dark in color, usually follow the lines of
Blaschko, and exhibit epidermal hyper-
keratosis, papillomatosis, and acanthosis
(Figure 1a–c; Nguyen et al., 2004). EN
are generally noticed in the first year of
life and are stable in extent, whereas
CCTN grow progressively after first
appearing later in the first or second
year (Twede et al., 2005).
It is unknown which cells determine
the formation of these lesions. On the
basis of the histology, we hypothesized
that CCTN were generated by AKT1
p.Glu17Lys in the dermis and that EN
were generated by this mutation in the
epidermis. To test this hypothesis, we
isolated fibroblasts and keratinocytes
from lesional (CCTN or EN) and non-
lesional (‘‘normal’’) skin samples and
measured the level of the mutant allele
in each cell type.
Skin samples were collected during
surgical procedures or by punch biop-
sies from patients with PS under an
institutional review board-approved
protocol. The epidermis was separated
from the dermis by treatment withAccepted article preview online 24 July 2013; published online 15 August 2013
Abbreviations: CCTN, cerebriform connective tissue nevi; EN, epidermal nevi; PS, proteus syndrome
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Figure 1. Representative examples of an epidermal nevi (EN) and cerebriform connective tissue nevi (CCTN). Panel a shows the rough surface of the linear EN on
the infraaxillary vault in patient 101. Hematoxylin and eosin stain (b, scale bar¼ 100mm; c, scale bar¼ 50mm) of a skin biopsy from the EN in panel a. The lesion
is characterized by papillomatosis, mild hyperkeratosis, and acanthosis. Panel d shows the CCTN encompassing the hallux of patient 75. Hematoxylin and
eosin stain of skin obtained after amputation of the hallux (e, scale bar¼100mm; f, scale bar¼ 50mm). Note the extensive dense collagen matrix, compression of
the papillary dermis, and the smooth surface of the lesion.
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Figure 2. Percentage of AKT1 c.49G4A, p.Glu17Lys mutation in epidermal and dermal cells and tissue. One keratinocyte culture (left panel) was established
from each epidermal sample. Mutation percentages are indicated by the blue circles. Multiple fibroblast cultures (right panel) were established from most
pieces of dermal tissue. The mutation percentage for each fibroblast culture is indicated by a green circle. The mean mutation percentage for the fibroblast cultures
from each sample is indicated by a green square and the mutation percentage in residual dermal tissue post culture is indicated by a yellow triangle. Samples
are ordered from lowest to highest mutation value (keratinocytes) or mean mutation value (fibroblasts) and are color coded as follows: epidermal nevi, red;
cerebriform connective tissue nevi, black; unaffected/unknown, light blue.
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dispase, and keratinocyte and fibroblast
cultures were established using standard
protocols (Aasen and Belmonte, 2010).
A single keratinocyte culture was
established from each biopsy.
Fibroblasts were allowed to grow out
of the dermal tissue until the dish
was confluent. The dermal tissue was
then transferred to a new dish to
allow another fibroblast culture to be
established from that same tissue. The
number of fibroblast cultures established
from a piece of dermis ranged from one
to six. DNA was isolated from cultured
cells harvested between passages one
and four, and the mutation level was
assayed using a PCR-based restriction
fragment length polymorphism assay as
described (Lindhurst et al., 2011). This
assay has a lower limit of sensitivity of
0.5%. Each DNA preparation was tested
at least twice and the values were
averaged. In 10 of the 20 samples,
DNA was also isolated from the
dermal tissue used to establish the
fibroblast cultures after the final transfer.
Seven CCTN biopsies were obtained
from the feet of three patients (Supple-
mentary Table S1 online). The mutant
allele was not detected in CCTN kerati-
nocyte cultures, whereas the mutation
level from the CCTN fibroblast cultures
was 9–32%. In the dermal tissue
post-culturing, the mutation level was
12–21% (Figure 2).
Nine EN samples were obtained from
the hand, trunk, or neck from seven
patients (Supplementary Table S1
online). The mutation level in the kera-
tinocyte cultures was 0–44%, whereas
the mutation level in the fibroblast cul-
tures was 0–41%. The mutation level in
the cultured dermal tissue was 9–25%.
Interestingly, the two samples with the
highest levels of mutation in the kerati-
nocytes (101EN1 and 78EN2) had the
lowest mutation percentages in dermal
cells or tissue. Detection of the mutant
allele in the EN keratinocytes is consis-
tent with the identification of the AKT1
p.Glu17Lys mutation in skin scrapings
of PS EN (Wieland et al., 2013).
Four biopsies from two patients were
obtained from tissue that appeared nor-
mal by gross examination, but was from
an area that was far removed from
lesional tissue (designated as unaffected)
or bordered a CCTN (designated as
unknown; Supplementary Table S1
online). No evidence of the mutant
allele was present in the keratinocyte
cultures. The mean mutation level in the
fibroblast cultures was 6–27%.
We conclude that the AKT1
p.Glu17Lys activating mutation in kera-
tinocytes is a key determinant of EN
formation. Mutations in the FGFR3,
PIK3CA, and RAS genes have been
identified in epidermal cells of EN not
associated with PS, supporting this
hypothesis (Hafner et al., 2006, 2007,
2012). Histopathologically, these
keratinocytic EN are strikingly similar
to those found in PS, and it should be
noted that PIK3CA encodes the catalytic
subunit of the PI3K complex, which
functions upstream of AKT in the same
signaling pathway. In contrast, there
was no correlation of the mutation
levels in fibroblasts or cultured dermal
tissue with the clinical lesion type. The
inability to detect an AKT1 mutation in
two of the EN keratinocyte cultures
could be due to a sampling artifact if
the mutant cells were not uniformly
distributed throughout the lesion and
the sample was from an area with low-
level mosaicism. It seems unlikely that
the lack of mutant keratinocytes in some
EN indicates that these lesions form as a
result of signaling from mutant cells in
the dermis, as even organoid EN, such
as nevus sebaceous, have been shown
to result from mutant cells in the
epidermis (Groesser et al., 2012).
Mutant cells were found in dermal
fibroblasts of both CCTN and normal-
appearing skin, suggesting that the
presence of mutant cells in the dermis
is necessary but not sufficient to drive
the formation of CCTN. The propensity
of CCTNs to develop on soles and palms
in PS may reflect a greater role of AKT1
in postnatal regulation of tissue archi-
tecture at these sites than elsewhere on
the skin.
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TO THE EDITOR
Histamine is the best known pruritogen
in humans and the most commonly used
experimental itch-causing substance. It
induces increased itch responses in the
lesional skin of atopic dermatitis (AD)
patients compared with normal skin
(Ikoma et al., 2006). However,
histamine H1 receptor (H1R) antagonists
frequently fail to relieve the itch in AD
patients as well as it does in patients
with systemic diseases such as kidney
and liver diseases. The lack of amelio-
ration by high-potency H1R antagonists
of different types in patients with itch
suggests that other systems are involved
(Ikoma et al., 2006; Sta¨nder and
Weisshaar, 2012).
Involvement of histamine H4 receptor
(H4R) in histamine-evoked itch in ani-
mal models has been reported (Dunford
et al., 2007; Thurmond et al., 2008).
However, the therapeutic efficacy of
H4R antagonists on the H1R antagonist-
resistant itch in AD is poorly under-
stood. We therefore examined the
therapeutic effects of H4R antagonists
on itch and skin inflammation in AD
using NC/Nga mice, a mouse model of
AD that has been previously described
(Tanaka et al., 2012).
Male NC/Nga mice (Charles River
Japan, Yokohama, Japan), 10 weeks
old, were maintained in clean condi-
tion. All animal procedures were appro-
ved by the institutional Animal Care and
Use Committee of Juntendo University
Graduate School of Medicine. It is gene-
rally accepted worldwide that AD patients
are highly sensitized to house dust
mite allergens (Sanda et al., 1992); and
that house dust mite Dermatophagoides
farinae body (Dfb) and feces are well-
known major environmental allergens
(Matsuoka et al., 1995). We used a Dfb
ointment-induced AD-like mouse model
(Dfb-NC/Nga) to evaluate the thera-
peutic efficacy of H4R antagonists
against itch-related behavior (scratching)
and dermatitis in a mouse model of AD.
Dermatitis was induced by applica-
tion of Dfb ointment (Biostir, Kobe,
Japan) twice a week for 3 weeks as des-
cribed (Yamamoto et al., 2009). Severity
of skin lesion was graded according to
the criteria as described (Matsuda et al.,
1997). Animals that received repeated
application of Dfb ointment to their skin
(Figure 1a) showed higher dermatitis
scores than controls after 3 weeks (data
not shown). After the induction, transe-
pidermal water loss was measured using
a Tewameter TM210 (Courage and Kha-
zawa, Cologne, Germany) and scratch-
ing behavior was observed for 2 hours
using a MicroAct (Neuroscience, Tokyo,
Japan) as described (Inagaki et al., 2003).
Dfb-NC/Nga mice showed significant
loss of transepidermal water and more
scratching bouts (data not shown).
We examined effects of H4R antago-
nists, JNJ7777120 and JNJ28307474, on
dermatitis and scratching behavior in
Dfb-NC/Nga mice. In mice, antagonist
JNJ28307474 shows a longer plasma
half-life than JNJ7777120 (Thurmod
et al., unpublished observations). Mice
that scored over 5 for dermatitis severity
were treated by either intraperito-
neal injection with a vehicle (20%
dimethylsulphoxide and 80% 2-hydro-
xypropyl-b-cyclodextrin in saline) or
H4R antagonists (10 or 30 mg kg
1)
three times per week for 3 weeks
(Figure 1a). Dermatitis score was asses-
sed after each Dfb application, and the
data were expressed as fold change
values over score of dermatitis before
H4R antagonist treatment (baseline) in
each group. No significant amelio-
ration of dermatitis followed treat-
ment by either of these H4R antagonists
(Figure 1b and c). In addition, scratching
behavior was recorded before and after
H4R antagonist treatment (# shown in
Figure 1a). The data were expressed as
fold change values over number of
scratching bouts before the treatment
(baseline) in each group. Behavior ana-
lyses revealed neither treatment inhi-
bited scratching behavior (Figure 1d
and e). Moreover, the fold change
value of scratching bouts significantly
increased by treatment of 30 mg kg1
JNJ28307474 (Figure 1e). Treatment
with JNJ7777120 or JNJ28307474 had
no effect on locomotion activity (Kamo
et al., unpublished observations).
In this study, we found that treatment
with H4R antagonist (JNJ7777120 orAccepted article preview online 20 August 2013; published online 19 September 2013
Abbreviations: AD, atopic dermatitis;; Dfb, Dermatophagoides farinae body; H1R, histamine H1 receptor;
H4R, histamine H4 receptor
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